COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (MJ-ADHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02803229
Recruitment Status : Recruiting
First Posted : June 16, 2016
Last Update Posted : February 7, 2020
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Frances R Levin, New York State Psychiatric Institute

Brief Summary:
The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and benefit of Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR) in the treatment of individuals with Cannabis Use Disorder (CUD) and Attention-deficit/Hyperactivity Disorder (ADHD). The investigators plan to enroll 50 and randomize 40 of these patients in the trial. The primary objective of the study is to determine the efficacy of MAS-XR in promoting cannabis abstinence among individuals with CUD and in promoting a decrease of ADHD symptoms.

Condition or disease Intervention/treatment Phase
Cannabis Use Disorder Attention-deficit/Hyperactivity Disorder Drug: Adderall-XR Drug: Matched placebo Phase 2 Phase 3

Detailed Description:

ADHD is common in substance use disorder patients in general and cannabis use disorder (CUD) in particular, occurring at rates substantially greater than in the general population. A meta-analysis found that approximately 23% of substance abusers seeking treatment have childhood and/or adult ADHD. Moreover, ADHD was overrepresented in adults with CUD compared to other substance use disorder patients seeking treatment. The importance in treating CUD individuals who also have ADHD is underscored by findings demonstrating that individuals with co-occurring ADHD and substance use disorders are a particularly intractable group: they exhibit earlier onset of use, more severe use, a more complicated pattern of remission/relapse, and poorer treatment outcomes relative to those without ADHD. Yet, to date, ADHD individuals with CUD have not been adequately studied. The investigators have found that in their treatment research studies targeting cannabis dependence that a substantial percentage (35%) have screened positive for adult ADHD, rates that are higher than participants in their cocaine use disorder clinical trial and almost 8x greater than rates found in the general population. Thus, this appears to be a sizable cannabis-abusing group warranting much greater clinical attention than they are currently receiving.

The goal is to demonstrate feasibility, tolerability, and estimate effect size for purposes of planning future more definitive trials. Because of the research team's extensive experience in working with stimulant medication in treating ADHD in cocaine-dependent populations, the large effect size of amphetamine in treating adult ADHD, and notable reduction in cocaine use and ADHD symptoms in cocaine-dependent ADHD adults, the investigators will explore the efficacy of Adderall-XR (MAS-XR) for the treatment of cannabis use disorder and ADHD. The study is a 12 week placebo controlled double-blind trial. The maximum maintained dose will be 80 mg of MAS-XR daily.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
Actual Study Start Date : July 2016
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
matched Placebo arm
Drug: Matched placebo
matched placebo provided for placebo arm
Other Name: placebo

Experimental: Adderall-XR
Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
Drug: Adderall-XR
Other Name: Extended-release mixed amphetamine salt

Primary Outcome Measures :
  1. Marijuana abstinence [ Time Frame: Change from baseline compared to last 2 weeks of the 12 week study on maintained dose (weeks 10 and 11 for completers) or last 2 weeks of participants' participation during the study for participants who drop out of the study before weeks 10 and 11 ]
    defined as abstinence from marijuana during the last two weeks of the trial as recorded by theTimeline Followback method and confirmed by urine toxicology.

  2. Reduction in ADHD symptoms [ Time Frame: Change from baseline compared to last week of trial on maintained dose during the 12 week trial (week 11 for completers) or last week of participants' participation during the 12 week trial for those who drop out of study prior to week 11. ]
    The primary ADHD outcome measure will be the percentage of individuals who achieve at least a 30% reduction in symptom severity as measured by the Adult ADHD Interview Rating Scale (AISRS).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individuals who meet criteria for cannabis use disorder (CUD) and report that marijuana is their primary drug of abuse
  • Individuals must report using marijuana at least 5 days a week over the past 28 days and have a positive urine test for THC on the day of study entry
  • Individuals must meet DSM-5 criteria for adult ADHD
  • Individuals who score > 22 on the AISRS scale
  • Individuals between the ages of 18-65 capable of giving informed consent and capable of complying with study procedures
  • Women of child-bearing age will be included if they: a) are not pregnant, b) agree to use an effective method of contraception, c) agree not to become pregnant during the study and d) are not breastfeeding. To confirm this, urine pregnancy tests will be repeated every month after screening. Women will be provided a full explanation of the potential dangers of pregnancy while taking MAS-XR. If a woman becomes pregnant, she will be taken off medication and continue standard treatment at STARS. At the end of the study, patients will be offered treatment at STARS until an appropriate referral can be made to a community clinic.

Exclusion Criteria:

  • Individuals meeting DSM-5 criteria for schizophrenia, schizoaffective illness, psychotic disorder other than transient psychosis due to drug abuse, current major depression, bipolar illness or psychiatric disorders (other than substance abuse) which require psychiatric intervention or would interfere with study participation
  • Individuals who are medically unstable based on laboratory tests, electrocardiogram, medical history, physical examination that would make participation hazardous
  • Use of synthetic cannabinoids in the past month and meeting CUD diagnosis based on synthetic cannabinoids use alone in the past year
  • Individuals with liver enzyme function tests greater than 3 times normal
  • Individuals with significant current suicidal risk
  • Individuals with systolic blood pressure > 140; diastolic blood pressure >90; pulse >100
  • Individuals who are cognitively impaired to impede study participation
  • Nursing mothers and pregnant women
  • Individuals who are physiologically dependent on any other drugs (excluding nicotine) that would require a medical intervention
  • Individuals with known sensitivity/allergy to MAS-XR or amphetamine analogs
  • Individuals currently being prescribed psychotropic medication (including sleep medication)
  • Individuals with history of seizures
  • Individuals who are mandated to treatment
  • Individuals with a history of amphetamine use disorders, including amphetamines such as methamphetamine and MDMA.
  • Individuals with a current cocaine use disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02803229

Layout table for location contacts
Contact: Amy Mahony, LMHC 646-774-8183
Contact: Elizabeth Martinez 212-923-3031

Layout table for location information
United States, New York
New York Psychiatric Institute Recruiting
New York, New York, United States, 10032
Contact: Elizabeth Martinez    212-923-3031      
Principal Investigator: Frances R Levin, MD         
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Frances R Levin, MD New York Psychiatric Institute

Layout table for additonal information
Responsible Party: Frances R Levin, Research Psychiatrist, New York State Psychiatric Institute Identifier: NCT02803229    
Other Study ID Numbers: 7280
U54DA037842-01 ( U.S. NIH Grant/Contract )
First Posted: June 16, 2016    Key Record Dates
Last Update Posted: February 7, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Substance-Related Disorders
Chemically-Induced Disorders
Central Nervous System Stimulants
Physiological Effects of Drugs